Kamada Ltd. (NASDAQ: KMDA) has announced a robust start to 2025, with first-quarter revenue climbing 17% to $44.0 million and Adjusted EBITDA soaring 54% to $11.6 million compared to the same period last year. This performance underscores the company's ability to sustain growth through a diversified product portfolio and operational efficiency.
The company's growth was driven by strong sales of GLASSIA® and KAMRAB® in non-U.S. markets, alongside contributions from VARIZIG® and royalty income from GLASSIA. These products cater to critical health needs, including treatments for emphysema caused by Alpha 1-antitrypsin deficiency, rabies prevention, and varicella disease prophylaxis in high-risk individuals.
Kamada's strategic initiatives, including the expansion of its plasma collection operations with a new center in San Antonio, Texas, and a significant contract for KAMRAB and VARIZIG in Latin America, highlight its commitment to reducing dependency on third-party suppliers and enhancing its market presence. The company also continues to advance its InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy, aiming to address unmet needs in AATD patients.
With reiterated guidance for 2025 projecting revenue between $178 million and $182 million and Adjusted EBITDA of $38 million to $42 million, Kamada is poised for continued growth. The company's focus on organic growth, strategic acquisitions, and product development positions it as a key player in the biopharmaceutical industry, with implications for healthcare providers, patients, and investors alike.
